Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VRTX Vertex Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: VRTX
Price (delayed)
$447.51
Market cap
$114.92B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.82
Enterprise value
$111.89B
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather
Highlights
VRTX's revenue is up by 9% YoY
The gross profit has grown by 8% YoY
VRTX's debt has soared by 129% YoY
Vertex Pharmaceuticals's net income has shrunk by 125% YoY and by 85% QoQ
Key stats
What are the main financial stats of VRTX
Market
Valuations
Earnings
Shares outstanding
256.8M
Market cap
$114.92B
Enterprise value
$111.89B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.97
Price to sales (P/S)
10.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.08
Revenue
$11.1B
Gross profit
$9.55B
Operating income
-$740.5M
Net income
-$988.9M
EBIT
-$277M
EBITDA
-$74.9M
Free cash flow
-$1.25B
Per share
Balance sheet
Liquidity
EPS
-$3.82
EPS diluted
-$3.89
Free cash flow per share
-$4.87
Book value per share
$64.24
Revenue per share
$43.21
TBVPS
$83.11
Total assets
$22.88B
Total liabilities
$6.38B
Debt
$1.65B
Equity
$16.5B
Working capital
$6.23B
Debt to equity
0.1
Current ratio
2.65
Quick ratio
2.12
Net debt/EBITDA
40.4
Margins
Efficiency
Dividend
EBITDA margin
-0.7%
Gross margin
86%
Net margin
-8.9%
Operating margin
-6.7%
Return on assets
-4.5%
Return on equity
-6.2%
Return on invested capital
-2.1%
Return on capital employed
-1.5%
Return on sales
-2.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRTX stock price
How has the Vertex Pharmaceuticals stock price performed over time
Intraday
1.55%
1 week
3.59%
1 month
-8.5%
1 year
0.37%
YTD
11.13%
QTD
-7.7%
Financial performance
How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$11.1B
Gross profit
$9.55B
Operating income
-$740.5M
Net income
-$988.9M
Gross margin
86%
Net margin
-8.9%
Vertex Pharmaceuticals's net income has shrunk by 125% YoY and by 85% QoQ
VRTX's net margin has shrunk by 123% YoY and by 82% QoQ
The operating income has dropped by 118% year-on-year
The operating margin has shrunk by 116% YoY
Price vs fundamentals
How does VRTX's price correlate with its fundamentals
Growth
What is Vertex Pharmaceuticals's growth rate over time
Valuation
What is Vertex Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.97
P/S
10.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.08
The EPS has dropped by 125% year-on-year and by 84% since the previous quarter
The equity has contracted by 11% YoY
The stock's price to book (P/B) is 7% less than its last 4 quarters average of 7.4 but 6% more than its 5-year quarterly average of 6.5
VRTX's revenue is up by 9% YoY
The price to sales (P/S) is 6% less than the last 4 quarters average of 10.9 but 6% more than the 5-year quarterly average of 9.6
Efficiency
How efficient is Vertex Pharmaceuticals business performance
The return on sales has dropped by 200% since the previous quarter and by 105% year-on-year
The return on invested capital has dropped by 191% since the previous quarter and by 103% year-on-year
The return on equity has dropped by 126% year-on-year and by 88% since the previous quarter
VRTX's return on assets has dropped by 125% year-on-year and by 88% since the previous quarter
Dividends
What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRTX.
Financial health
How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's quick ratio has decreased by 33% YoY and by 2.3% QoQ
Vertex Pharmaceuticals's current ratio has decreased by 24% YoY
VRTX's debt is 90% lower than its equity
The debt to equity has soared by 150% YoY
VRTX's debt has soared by 129% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.